Cardiac Monitoring's Growing Role in Metabolic Disease Drug Trials

Cardiac Monitoring’s Growing Role in Metabolic Disease Drug Trials GLP-1 drugs have reshaped the treatment landscape for obesity, Type 2 diabetes, and increasingly, cardiovascular disease itself, and their rapid rise has intensified pressure on sponsors to bring new metabolic treatments to market faster. But the patients enrolling in these trials are often already managing elevated cardiovascular risk before they take a single dose, and the drugs themselves can carry cardiac effects worth tracking closely. As metabolic drug development accelerates, continuous cardiac monitoring gives trial tea